Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01502228 · ClinicalTrials.gov registry record · NA
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
A NA study, sponsored by Indiana University.
- Terminated
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT01502228: Clinical Trial NA study, sponsored by Indiana University.
NCT01502228 is a NA study that was terminated before completion, run by Indiana University. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01502228, a NA study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.
Primary Outcome
Number of patients who had at least a baseline measurement of 62Cu-ETS PET and 15O-water PET
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG Sunitinib
- DRUG 150-Water
- DRUG 62Cu-ethylglyoxal bis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-02 |
| Phase | NA |
Why NCT01502228 stopped before completion
NCT01502228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT01502228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01502228 about?
NCT01502228 is a clinical study titled "PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma". Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of ...
What is the current status of trial NCT01502228?
This trial is currently terminated. It is a NA study. The enrollment target is 14 participants. The study started on 2011-10. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01502228?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Sunitinib (DRUG), 150-Water (DRUG), 62Cu-ethylglyoxal bis (DRUG).
Who is sponsoring clinical trial NCT01502228?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01502228's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia